Back to top
more

Conatus Pharmaceuticals Inc. (CNAT)

(Delayed Data from NSDQ)

$0.90 USD

0.90
746,677

+0.05 (5.88%)

Updated May 3, 2019 03:59 PM ET

After-Market: $0.90 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

1 item in cart

View Cart/Checkout

Histogen Inc. [CNAT]

Reports for Purchase

Showing records 201 - 220 ( 226 total )

Company: Histogen Inc.

Industry: Medical - Products

Record: 201

03/16/2015

Industry Report

Pages: 3

Healthcare - Conference Update

Provider: Roth Capital Partners, Inc.

Analyst: PIROS E

Price: 10.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 202

03/03/2015

Company Report

Pages: 4

Transferring Coverage

Provider: Roth Capital Partners, Inc.

Analyst: MARTIN J

Price: 10.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 203

02/18/2015

Industry Report

Pages: 4

Healthcare - Biotechnology/Biopharma: 27th Annual ROTH Conference: Healthcare Track Preview

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 204

01/09/2015

Company Report

Pages: 11

Equivocal Response in ACLF Trial; Lowering Target to $12

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 205

01/09/2015

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 206

11/25/2014

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 207

11/25/2014

Company Report

Pages: 9

Takeaways from Investor Meetings; Affirm Buy

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 208

11/20/2014

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 209

11/19/2014

Company Report

Pages: 9

Corporate Access Event

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 210

11/14/2014

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 211

11/13/2014

Company Report

Pages: 6

3Q Recap; Preparing for a Busy Year of Trial Readouts in 2015; Affirm Buy

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 212

10/09/2014

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 213

10/08/2014

Daily Note

Pages: 5

IN AASLD Late-Breaker, Emricasan Single Dose Rapidly Reduces Biomarkers

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 214

08/14/2014

Company Report

Pages: 6

2Q14; NASH Trial Results Delay is a Non-Issue; Affirm Buy

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 215

08/14/2014

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 216

08/12/2014

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 217

08/12/2014

Company Report

Pages: 5

FLINT Data Highlights Potential for Disease-Modifying Activity in NASH

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 218

06/13/2014

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 219

06/13/2014

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Histogen Inc.

Industry: Medical - Products

Record: 220

06/13/2014

Company Report

Pages: 16

We assume coverage with a Buy rating and $19.00 price target

Provider: Roth Capital Partners, Inc.

Price: 50.00

Research Provided by a Third Party